Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
School of Pharmacy, Fudan University, Pudong, Shanghai, China. In 2024, the China National Medical Products Administration (NMPA) approved a total of 228 new drug applications (NDAs), including ...
China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the ...
Up to date, HANSIZHUANG has been approved by the National Medicinal Products Administration (NMPA) for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell ...
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...
Pharmaceuticals announced the NMPA, National Medical Products Administration, approval of Cumberland’s Vibativ injection in ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal allergic rhinitis. The approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback